Fibroblast growth factor - ViaCell

Drug Profile

Fibroblast growth factor - ViaCell

Alternative Names: dFGF - ViaCell; Dimerised fibroblast growth factor - ViaCell

Latest Information Update: 09 Apr 2008

Price : $50

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer ViaCell
  • Class Fibroblast growth factors
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 09 Apr 2008 Discontinued - Preclinical for Stroke in USA (unspecified route)
  • 08 Nov 2005 No development reported - Preclinical for Stroke in USA (unspecified route)
  • 02 Sep 2002 Preclinical trials in Stroke in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top